These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28424841)

  • 1. Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer.
    Ogino I; Watanabe S; Sakamaki K; Ogino Y; Kunisaki C; Kimura K
    Strahlenther Onkol; 2017 Jul; 193(7):552-560. PubMed ID: 28424841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients.
    Fukada J; Shigematsu N; Takeuchi H; Ohashi T; Saikawa Y; Takaishi H; Hanada T; Shiraishi Y; Kitagawa Y; Fukuda K
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):487-93. PubMed ID: 23968770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer.
    Xue J; Han C; Jackson A; Hu C; Yao H; Wang W; Hayman J; Chen W; Jin J; Kalemkerian GP; Matuzsak M; Jolly S; Kong FS
    Radiother Oncol; 2019 Apr; 133():213-219. PubMed ID: 30416046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of cardiac toxicity after definitive chemoradiotherapy for esophageal cancer using a biological dose-volume histogram.
    Takeuchi Y; Murakami Y; Kameoka T; Ochi M; Imano N; Takahashi I; Nishibuchi I; Kimura T; Kawahara D; Saito A; Nagata Y
    J Radiat Res; 2020 Mar; 61(2):298-306. PubMed ID: 32052040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy.
    Wei X; Liu HH; Tucker SL; Wang S; Mohan R; Cox JD; Komaki R; Liao Z
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):707-14. PubMed ID: 18191334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer.
    Pao TH; Chang WL; Chiang NJ; Lin CY; Lai WW; Tseng YL; Lin FC
    Radiat Oncol; 2020 Feb; 15(1):48. PubMed ID: 32103779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy.
    Tamari K; Isohashi F; Akino Y; Suzuki O; Seo Y; Yoshioka Y; Hayashi Y; Nishida T; Takehara T; Mori M; Doki Y; Ogawa K
    Anticancer Res; 2014 Dec; 34(12):7389-93. PubMed ID: 25503178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer.
    Ogino I; Watanabe S; Iwahashi N; Kosuge M; Sakamaki K; Kunisaki C; Kimura K
    Strahlenther Onkol; 2016 Jun; 192(6):359-67. PubMed ID: 26884226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-comparison of four-field technique and traditional two opposed fields technique.
    Takata N; Kataoka M; Hamamoto Y; Tsuruoka S; Kanzaki H; Uwatsu K; Nagasaki K; Mochizuki T
    J Radiat Res; 2018 May; 59(3):291-297. PubMed ID: 29659940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac radiation dose predicts survival in esophageal squamous cell carcinoma treated by definitive concurrent chemotherapy and intensity modulated radiotherapy.
    Pao TH; Chang WL; Chiang NJ; Chang JS; Lin CY; Lai WW; Tseng YL; Yen YT; Chung TJ; Lin FC
    Radiat Oncol; 2020 Sep; 15(1):221. PubMed ID: 32962730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy.
    Hayashi K; Fujiwara Y; Nomura M; Kamata M; Kojima H; Kohzai M; Sumita K; Tanigawa N
    Br J Radiol; 2015 Feb; 88(1046):20140168. PubMed ID: 25429644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis.
    Makishima H; Ishikawa H; Terunuma T; Hashimoto T; Yamanashi K; Sekiguchi T; Mizumoto M; Okumura T; Sakae T; Sakurai H
    J Radiat Res; 2015 May; 56(3):568-76. PubMed ID: 25755255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer.
    Fukada J; Shigematsu N; Ohashi T; Shiraishi Y; Takeuchi H; Kawaguchi O; Kitagawa Y
    J Radiat Res; 2012; 53(3):447-53. PubMed ID: 22739014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer.
    He L; Chapple A; Liao Z; Komaki R; Thall PF; Lin SH
    Radiother Oncol; 2016 Oct; 121(1):70-74. PubMed ID: 27562616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-volume histogram parameters and clinical factors associated with pleural effusion after chemoradiotherapy in esophageal cancer patients.
    Shirai K; Tamaki Y; Kitamoto Y; Murata K; Satoh Y; Higuchi K; Nonaka T; Ishikawa H; Katoh H; Takahashi T; Nakano T
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1002-7. PubMed ID: 20542385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric predictors of acute haematological toxicity in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy.
    Lee J; Lin JB; Sun FJ; Lu KW; Lee CH; Chen YJ; Huang WC; Liu HC; Wu MH
    Br J Radiol; 2016 Oct; 89(1066):20160350. PubMed ID: 27556422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.
    Wang SL; Liao Z; Vaporciyan AA; Tucker SL; Liu H; Wei X; Swisher S; Ajani JA; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):692-9. PubMed ID: 16242257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.
    Hayashi Y; Iijima H; Isohashi F; Tsujii Y; Fujinaga T; Nagai K; Yoshii S; Sakatani A; Hiyama S; Shinzaki S; Makino T; Yamasaki M; Ogawa K; Doki Y; Takehara T
    BMC Cancer; 2019 Mar; 19(1):195. PubMed ID: 30832605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of dosimetric and clinical factors with the development of esophagitis and radiation pneumonitis in patients with limited-stage small-cell lung carcinoma.
    Giuliani ME; Lindsay PE; Kwan JY; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
    Clin Lung Cancer; 2015 May; 16(3):216-20. PubMed ID: 25532963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT.
    Münch S; Aichmeier S; Hapfelmeier A; Duma MN; Oechsner M; Feith M; Combs SE; Habermehl D
    Strahlenther Onkol; 2016 Oct; 192(10):722-9. PubMed ID: 27418129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.